Site icon The Rojak Pot

Malaysia Approves COVAXIN Inactivated Virus Vaccine!

Malaysia Approves COVAXIN Inactivated Virus Vaccine!

Malaysia just approved the COVAXIN inactivated virus vaccine for use against COVID-19!

Here is what you need to know!


Malaysia Approves COVAXIN Inactivated Virus Vaccine!

On 10 February 2022, the Malaysia Ministry of Health (KKM) announced that the Drug Control Authority (DCA) has agreed to conditionally approve the COVAXIN vaccine for use against COVID-19!

COVAXIN® (Whole Virion, Inactivated Coronavirus (SARS-CoV-2) Vaccine) Suspension for Intramuscular Injection

The COVAXIN vaccine is now allowed to be given to individuals 18 years and older in Malaysia.


COVAXIN Vaccine : A Quick Primer

Codenamed BBV152, the Bharat COVAXIN vaccine is an inactivated virus vaccine, similar to the Sinovac CoronaVac vaccine.

It is manufactured from actual COVID-19 viruses that were grown in Vero cells, and inactivated using beta-propiolactone. It uses an aluminium-based adjuvant called Alhydroxiquim-II to stimulate the immune response.

COVAXIN is a 2-dose vaccine, with each 5 ml dose given intramuscularly. The second dose is given after an interval of 4 weeks.

Its Phase 3 trial showed that it was 78% effective in preventing symptomatic COVID-19, and 93% effective in preventing severe disease. It was also shown to be 65% effective against the Delta variant.


Please Support My Work!

Support my work through a bank transfer /  PayPal / credit card!

Name : Adrian Wong
Bank Transfer : CIMB 7064555917 (Swift Code : CIBBMYKL)
Credit Card / Paypal :

Dr. Adrian Wong has been writing about tech and science since 1997, even publishing a book with Prentice Hall called Breaking Through The BIOS Barrier (ISBN 978-0131455368) while in medical school.

He continues to devote countless hours every day writing about tech, medicine and science, in his pursuit of facts in a post-truth world.


Recommended Reading


Support Us!

If you like our work, please support us by visiting our sponsors, or donating to our fund. Thank you!

Exit mobile version